Details for Patent: 9,573,964
✉ Email this page to a colleague
Which drugs does patent 9,573,964 protect, and when does it expire?
Patent 9,573,964 protects VONJO and is included in one NDA.
This patent has forty-nine patent family members in twenty-one countries.
Summary for Patent: 9,573,964
| Title: | Oxygen linked pyrimidine derivatives |
| Abstract: | The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumors and cancers as well as other disorders or conditions related to or associated with kinases. |
| Inventor(s): | Blanchard; Stephanie (Singapore, SG), Lee; Cheng Hsia Angeline (Singapore, SG), Nagaraj; Harish Kumar Mysore (Singapore, SG), Poulsen; Anders (Singapore, SG), Sun; Eric T. (Singapore, SG), Tan; Yee Ling Evelyn (Singapore, SG), William; Anthony Deodaunia (Singapore, SG) |
| Assignee: | CTI BIOPHARMA CORP. (Seattle, WA) |
| Application Number: | 13/771,546 |
|
Patent Claim Types: see list of patent claims | Use; Device; |
Drugs Protected by US Patent 9,573,964
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cti Biopharma Corp | VONJO | pacritinib citrate | CAPSULE;ORAL | 208712-001 | Feb 28, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | USE OF PACRITINIB FOR INHIBITING JANUS ASSOCIATED KINASE 2(JAK2) | ⤷ Sign Up | ||||
| Cti Biopharma Corp | VONJO | pacritinib citrate | CAPSULE;ORAL | 208712-001 | Feb 28, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF MYELOFIBROSIS WITH PACRITINIB | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,573,964
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | E469158 | ⤷ Sign Up | |||
| Australia | 2006316071 | ⤷ Sign Up | |||
| Australia | 2006316072 | ⤷ Sign Up | |||
| Brazil | PI0618552 | ⤷ Sign Up | |||
| Canada | 2629443 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
